TRIM48
gene geneOn this page
Also known as RNF101
Summary
TRIM48 (tripartite motif containing 48, HGNC:19021) is a protein-coding gene on chromosome 11q11, encoding E3 ubiquitin-protein ligase TRIM48 (Q8IWZ4). E3 ubiquitin-protein ligase which promotes K48-linked polyubiquitination of protein methyltransferase PRMT1, leading to PRMT1 degradation.
Predicted to enable ubiquitin protein ligase activity. Predicted to be involved in innate immune response and regulation of gene expression. Located in cytosol.
Source: NCBI Gene 79097 — RefSeq curated summary.
At a glance
- GWAS associations: 11
- Clinical variants (ClinVar): 54 total
- MANE Select transcript:
NM_024114
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:19021 |
| Approved symbol | TRIM48 |
| Name | tripartite motif containing 48 |
| Location | 11q11 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | RNF101 |
| Ensembl gene | ENSG00000150244 |
| Ensembl biotype | protein_coding |
| Entrez | 79097 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000417545
RefSeq mRNA: 1 — MANE Select: NM_024114
NM_024114
CCDS: CCDS7947
Canonical transcript exons
ENST00000417545 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002210606 | 55262155 | 55262311 |
| ENSE00002439381 | 55264900 | 55265314 |
| ENSE00002458459 | 55268350 | 55268372 |
| ENSE00002467148 | 55269242 | 55269339 |
| ENSE00002490598 | 55270437 | 55271114 |
| ENSE00002513438 | 55265600 | 55265695 |
Expression profiles
Bgee: expression breadth tissue_specific, 3 present calls, max score 37.20.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0139 / max 18.1310, expressed in 3 samples.
FANTOM5 promoters (1 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 114246 | 0.0139 | 3 |
Top tissues by expression
131 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| colonic epithelium | UBERON:0000397 | 37.20 | gold quality |
| sural nerve | UBERON:0015488 | 36.58 | gold quality |
| ventricular zone | UBERON:0003053 | 36.48 | gold quality |
| cortical plate | UBERON:0005343 | 36.47 | gold quality |
| apex of heart | UBERON:0002098 | 36.26 | gold quality |
| bone marrow cell | CL:0002092 | 36.16 | gold quality |
| ganglionic eminence | UBERON:0004023 | 35.49 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 33.38 | gold quality |
| muscle tissue | UBERON:0002385 | 32.41 | gold quality |
| hindlimb stylopod muscle | UBERON:0004252 | 32.15 | gold quality |
| bone marrow | UBERON:0002371 | 31.74 | gold quality |
| stromal cell of endometrium | CL:0002255 | 29.87 | gold quality |
| prefrontal cortex | UBERON:0000451 | 29.21 | gold quality |
| skin of leg | UBERON:0001511 | 28.73 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 28.60 | silver quality |
| duodenum | UBERON:0002114 | 28.14 | gold quality |
| liver | UBERON:0002107 | 28.04 | gold quality |
| urinary bladder | UBERON:0001255 | 27.70 | gold quality |
| lymph node | UBERON:0000029 | 27.57 | gold quality |
| tonsil | UBERON:0002372 | 27.05 | gold quality |
| islet of Langerhans | UBERON:0000006 | 26.55 | gold quality |
| vermiform appendix | UBERON:0001154 | 26.42 | gold quality |
| leukocyte | CL:0000738 | 26.15 | gold quality |
| monocyte | CL:0000576 | 26.00 | gold quality |
| blood | UBERON:0000178 | 26.00 | gold quality |
| gall bladder | UBERON:0002110 | 25.98 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 25.89 | gold quality |
| placenta | UBERON:0001987 | 25.81 | gold quality |
| zone of skin | UBERON:0000014 | 25.79 | gold quality |
| muscle of leg | UBERON:0001383 | 25.12 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 3.28 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
52 targeting TRIM48, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-188-3P | 100.00 | 68.76 | 1240 |
| HSA-MIR-4776-3P | 100.00 | 68.73 | 1340 |
| HSA-MIR-6825-5P | 99.96 | 69.81 | 3431 |
| HSA-MIR-3143 | 99.93 | 71.96 | 3104 |
| HSA-MIR-6499-3P | 99.90 | 66.38 | 1212 |
| HSA-MIR-124-3P | 99.89 | 73.74 | 3043 |
| HSA-MIR-506-3P | 99.89 | 73.55 | 3057 |
| HSA-MIR-6875-3P | 99.82 | 70.26 | 2983 |
| HSA-MIR-204-5P | 99.79 | 71.62 | 2439 |
| HSA-MIR-211-5P | 99.79 | 71.65 | 2440 |
| HSA-MIR-3150A-3P | 99.76 | 64.44 | 1640 |
| HSA-MIR-6763-5P | 99.76 | 64.68 | 1767 |
| HSA-MIR-10393-3P | 99.72 | 66.56 | 961 |
| HSA-MIR-6801-5P | 99.72 | 66.50 | 981 |
| HSA-MIR-802 | 99.61 | 67.70 | 1254 |
| HSA-MIR-6861-3P | 99.60 | 68.46 | 444 |
| HSA-MIR-4762-5P | 99.57 | 68.54 | 1424 |
| HSA-MIR-1252-3P | 99.55 | 67.71 | 2862 |
| HSA-MIR-105-5P | 99.54 | 69.24 | 2060 |
| HSA-MIR-7853-5P | 99.54 | 69.30 | 2055 |
| HSA-MIR-122B-5P | 99.46 | 70.81 | 1457 |
| HSA-MIR-4762-3P | 99.43 | 69.72 | 2363 |
| HSA-MIR-3678-3P | 99.31 | 67.10 | 1432 |
| HSA-MIR-593-3P | 99.22 | 67.28 | 1327 |
| HSA-MIR-361-3P | 99.19 | 66.45 | 1381 |
| HSA-MIR-10399-5P | 99.17 | 69.87 | 2610 |
| HSA-MIR-6504-3P | 99.17 | 69.31 | 2891 |
| HSA-MIR-4784 | 99.15 | 67.41 | 1733 |
| HSA-MIR-323B-3P | 99.14 | 68.89 | 725 |
| HSA-MIR-7854-3P | 99.08 | 66.26 | 1117 |
Literature-anchored findings (GeneRIF, showing 1)
- TRIM48 Promotes ASK1 Activation and Cell Death through Ubiquitination-Dependent Degradation of the ASK1-Negative Regulator PRMT1 (PMID:29186683)
Cross-species orthologs
0 orthologs
Paralogs (80): MID2 (ENSG00000080561), TRIM9 (ENSG00000100505), MID1 (ENSG00000101871), MEFV (ENSG00000103313), TRIM35 (ENSG00000104228), TRIM14 (ENSG00000106785), TRIM37 (ENSG00000108395), TRIM2 (ENSG00000109654), TRIM3 (ENSG00000110171), TRIM38 (ENSG00000112343), TRIM62 (ENSG00000116525), TRIM67 (ENSG00000119283), TRIM32 (ENSG00000119401), BSPRY (ENSG00000119411), TRIM25 (ENSG00000121060), TRIM6 (ENSG00000121236), TRIM24 (ENSG00000122779), TRIM51 (ENSG00000124900), TRIM28 (ENSG00000130726), TRIM21 (ENSG00000132109), TRIM5 (ENSG00000132256), TRIM22 (ENSG00000132274), TRIM47 (ENSG00000132481), TRIM45 (ENSG00000134253), TRIM29 (ENSG00000137699), TRIM54 (ENSG00000138100), PML (ENSG00000140464), TRIM65 (ENSG00000141569), TRIM43B (ENSG00000144010), TRIM43 (ENSG00000144015), TRIM7 (ENSG00000146054), TRIM41 (ENSG00000146063), TRIM50 (ENSG00000146755), TRIM4 (ENSG00000146833), TRIM55 (ENSG00000147573), TRIM36 (ENSG00000152503), TRIM11 (ENSG00000154370), TRIM74 (ENSG00000155428), TRIM42 (ENSG00000155890), TRIM63 (ENSG00000158022)
Protein
Protein identifiers
E3 ubiquitin-protein ligase TRIM48 — Q8IWZ4 (reviewed: Q8IWZ4)
Alternative names: RING finger protein 101, Tripartite motif-containing protein 48
All UniProt accessions (1): Q8IWZ4
UniProt curated annotations — full annotation on UniProt →
Function. E3 ubiquitin-protein ligase which promotes K48-linked polyubiquitination of protein methyltransferase PRMT1, leading to PRMT1 degradation. This suppresses methylation of the PRMT1 substrate MAP3K5/ASK1, promoting its activation and increasing MAP3K5-dependent cell death induced by oxidative stress. TRIM48-mediated ubiquitination of PRMT1 also suppresses methylation of FOXO1 by PRMT1, leading to inhibition of FOXO1 transcriptional activity. Additionally, it inhibits RIG-I-mediated antiviral signaling, functioning as an inducible negative feedback regulator of this pathway.
Subunit / interactions. Interacts with PRMT1; the interaction leads to ubiquitination of PRMT1 by TRIM48. Interacts with MAP3K5. Interacts with STRAP.
Subcellular location. Cytoplasm. Cytosol.
Induction. Upon RIG-I/DDX58 stimulation.
Similarity. Belongs to the TRIM/RBCC family.
RefSeq proteins (1): NP_077019* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR000315 | Znf_B-box | Domain |
| IPR001841 | Znf_RING | Domain |
| IPR013083 | Znf_RING/FYVE/PHD | Homologous_superfamily |
| IPR050143 | TRIM/RBCC | Family |
Pfam: PF00643, PF15227
UniProt features (8 total): binding site 4, zinc finger region 2, chain 1, mutagenesis site 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8IWZ4-F1 | 81.33 | 0.37 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Ligand- & substrate-binding residues (4): 109; 112; 131; 137
Mutagenesis-validated functional residues (1):
| Position | Phenotype |
|---|---|
| 46 | abolishes prmt1 ubiquitination and map3k5 activation. |
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-877300 | Interferon gamma signaling |
MSigDB gene sets: 50 (showing top):
REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, MODULE_255, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, MODULE_317, IVANOVA_HEMATOPOIESIS_MATURE_CELL, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_PROTEASOMAL_PROTEIN_CATABOLIC_PROCESS, GOBP_PROTEIN_CATABOLIC_PROCESS, MODULE_69, GOBP_PROTEOLYSIS, GOMF_ACYLTRANSFERASE_ACTIVITY, GOMF_AMINOACYLTRANSFERASE_ACTIVITY, GOMF_UBIQUITIN_LIKE_PROTEIN_LIGASE_ACTIVITY, MOREAUX_MULTIPLE_MYELOMA_BY_TACI_UP, KRAS.600_UP.V1_DN
GO Biological Process (3): regulation of gene expression (GO:0010468), proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161), innate immune response (GO:0045087)
GO Molecular Function (5): zinc ion binding (GO:0008270), ubiquitin protein ligase activity (GO:0061630), protein binding (GO:0005515), transferase activity (GO:0016740), metal ion binding (GO:0046872)
GO Cellular Component (2): cytoplasm (GO:0005737), cytosol (GO:0005829)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| Interferon Signaling | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 2 |
| gene expression | 1 |
| regulation of macromolecule biosynthetic process | 1 |
| ubiquitin-dependent protein catabolic process | 1 |
| proteasomal protein catabolic process | 1 |
| immune response | 1 |
| defense response to symbiont | 1 |
| transition metal ion binding | 1 |
| ubiquitin-protein transferase activity | 1 |
| ubiquitin-like protein ligase activity | 1 |
| binding | 1 |
| catalytic activity | 1 |
| cation binding | 1 |
| intracellular anatomical structure | 1 |
| cytoplasm | 1 |
Protein interactions and networks
STRING
338 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| TRIM48 | PRAMEF13 | Q5VWM6 | 505 |
| TRIM48 | OR8J3 | Q8NGG0 | 505 |
| TRIM48 | PRAMEF1 | O95521 | 480 |
| TRIM48 | PRAMEF11 | O60813 | 480 |
| TRIM48 | KHDC1L | Q5JSQ8 | 479 |
| TRIM48 | OR5F1 | O95221 | 476 |
| TRIM48 | RFPL2 | O75678 | 471 |
| TRIM48 | OR5D16 | Q8NGK9 | 469 |
| TRIM48 | OR4A15 | Q8NGL6 | 448 |
| TRIM48 | OR8I2 | Q8N0Y5 | 447 |
| TRIM48 | OR5T2 | Q8NGG2 | 447 |
| TRIM48 | OR5D14 | Q8NGL3 | 447 |
| TRIM48 | OR8H2 | Q8N162 | 447 |
| TRIM48 | KBTBD3 | Q8NAB2 | 445 |
| TRIM48 | OR5AS1 | Q8N127 | 436 |
IntAct
4 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| TRIM48 | NME7 | psi-mi:“MI:0915”(physical association) | 0.560 |
| NME7 | TRIM48 | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (5): PRMT1 (Affinity Capture-Western), PRMT1 (Biochemical Activity), TRIM48 (Two-hybrid), TRIM48 (Co-localization), TRIM48 (Affinity Capture-Western)
ESM2 similar proteins: A0A3B3IT33, A6NCK2, A6NDI0, A6NGJ6, A6NI03, A6NLI5, C9J1S8, I1YAP6, K7N6K2, P0CI25, P0CI26, P86449, Q0PF16, Q1ACD5, Q1ACD6, Q1ACD7, Q1ACD8, Q2YEM8, Q2YEM9, Q2YEN0, Q2YEN2, Q3ZEE5, Q587N6, Q587N7, Q5BN31, Q5C8T6, Q5C8T8, Q5C8U1, Q5C8U3, Q5C8U4, Q5D7H7, Q5D7H8, Q5D7I0, Q5D7I1, Q5D7I2, Q5D7I3, Q5D7I5, Q5D7I6, Q5D7I9, Q5D7J0
Diamond homologs: A0A3B3IT33, A6NCK2, A6NDI0, A6NGJ6, A6NI03, A6NLI5, B0BLU1, C9J1S8, I1YAP6, O00478, O00481, O15344, O75677, O75678, O75679, O76064, P0CI25, P0CI26, P18892, P19474, P62603, P86448, P86449, Q13410, Q2HJ46, Q3C1V9, Q3TL54, Q4KLN8, Q5EBN2, Q5PQN2, Q5R4I2, Q5R996, Q61510, Q62556, Q6INS5, Q6MFY8, Q6UX41, Q6UXE8, Q6ZWI9, Q7T308
SIGNOR signaling
1 interactions.
| A | Effect | B | Mechanism |
|---|---|---|---|
| Ub:E2 | “up-regulates activity” | TRIM48 | ubiquitination |
Disease & clinical
Clinical variants and AI predictions
ClinVar
54 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 51 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
710 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 11:55262308:AGCGG:A | donor_loss | 1.0000 |
| 11:55262309:GCG:G | donor_gain | 1.0000 |
| 11:55262310:CGGT:C | donor_loss | 1.0000 |
| 11:55262312:G:GG | donor_gain | 1.0000 |
| 11:55268344:TTACA:T | acceptor_loss | 1.0000 |
| 11:55268345:TACA:T | acceptor_loss | 1.0000 |
| 11:55268346:ACAGG:A | acceptor_loss | 1.0000 |
| 11:55268347:CAGGC:C | acceptor_loss | 1.0000 |
| 11:55268348:A:AC | acceptor_loss | 1.0000 |
| 11:55268348:A:AG | acceptor_gain | 1.0000 |
| 11:55268349:G:GA | acceptor_gain | 1.0000 |
| 11:55268349:G:T | acceptor_loss | 1.0000 |
| 11:55268373:G:GA | donor_loss | 1.0000 |
| 11:55268373:G:GG | donor_gain | 1.0000 |
| 11:55268374:T:A | donor_loss | 1.0000 |
| 11:55269238:GCA:G | acceptor_loss | 1.0000 |
| 11:55269240:A:AG | acceptor_gain | 1.0000 |
| 11:55269240:A:AT | acceptor_loss | 1.0000 |
| 11:55269241:G:GA | acceptor_gain | 1.0000 |
| 11:55269241:GGA:G | acceptor_gain | 1.0000 |
| 11:55269241:GGAGT:G | acceptor_gain | 1.0000 |
| 11:55269336:TGAGG:T | donor_loss | 1.0000 |
| 11:55269337:GAG:G | donor_gain | 1.0000 |
| 11:55269338:AG:A | donor_gain | 1.0000 |
| 11:55269338:AGG:A | donor_loss | 1.0000 |
| 11:55269339:GG:G | donor_gain | 1.0000 |
| 11:55269340:G:GG | donor_gain | 1.0000 |
| 11:55269341:T:G | donor_loss | 1.0000 |
| 11:55270435:A:AG | acceptor_gain | 1.0000 |
| 11:55270435:AGT:A | acceptor_gain | 1.0000 |
AlphaMissense
1499 scored. Top likely-pathogenic:
dbSNP variants (sampled 300 via entrez): RS1000011305 (11:55266266 A>C,G,T), RS1000131100 (11:55263435 T>C), RS1000160530 (11:55263576 C>T), RS1000334849 (11:55268410 C>G,T), RS1000487384 (11:55262857 A>T), RS1000612077 (11:55267653 T>A,C,G), RS1000687004 (11:55268650 G>A), RS1000767392 (11:55271487 T>A), RS1001291713 (11:55269689 T>C), RS1001742986 (11:55269463 A>G), RS1002903231 (11:55260827 C>G,T), RS1003500198 (11:55261682 C>T), RS1003506443 (11:55266000 TG>T), RS1003609812 (11:55265399 A>C,T), RS1003681643 (11:55270363 T>C,G)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
11 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST005580_137 | Intraocular pressure | 7.000000e-13 |
| GCST006624_128 | Systolic blood pressure | 1.000000e-16 |
| GCST006947_12 | Feeling fed-up | 2.000000e-09 |
| GCST008163_606 | Height | 8.000000e-06 |
| GCST009733_166 | Urinary metabolite levels in chronic kidney disease | 1.000000e-73 |
| GCST010241_199 | Apolipoprotein A1 levels | 4.000000e-25 |
| GCST010242_531 | HDL cholesterol levels | 7.000000e-47 |
| GCST010244_112 | Triglyceride levels | 8.000000e-09 |
| GCST012020_180 | Serum metabolite levels | 7.000000e-55 |
| GCST012020_208 | Serum metabolite levels | 2.000000e-50 |
| GCST012021_105 | Serum metabolite levels | 7.000000e-55 |
EFO canonical traits (7, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004695 | intraocular pressure measurement |
| EFO:0006335 | systolic blood pressure |
| EFO:0009588 | feeling “fed-up” measurement |
| EFO:0005116 | urinary metabolite measurement |
| EFO:0004614 | apolipoprotein A 1 measurement |
| EFO:0004612 | high density lipoprotein cholesterol measurement |
| EFO:0004530 | triglyceride measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
7 total (human), top 7 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Benzo(a)pyrene | decreases methylation, decreases expression | 2 |
| perfluorooctanoic acid | decreases expression | 1 |
| Acetaminophen | decreases expression | 1 |
| Calcitriol | increases expression, affects cotreatment | 1 |
| Malathion | decreases expression | 1 |
| Dihydrotestosterone | increases expression | 1 |
| Testosterone | affects cotreatment, increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.